TSTickerStarGet alerts

ENHA 10-Q filed 2026-11-13 | Key takeaways

ENHA filed its 10-Q; the most relevant disclosure change is added Subsequent events - reverse stock split: Company effected 1-for-10 reverse stock split effective October 29, 2026; every ten shares of Class A and Class B common stock combined into one share; fractional shares rounded up; par value and authorized shares unchanged.

Share this story

Key takeaways

  • Net loss improved to $13.5 million in Q3 2026 from $61.9 million in Q2 2026, as one-time costs of inaugural Enhanced Games and Business Combination did not recur

  • Company announced proposed acquisition of approximately 77% of DEAG Deutsche Entertainment AG from controlling shareholder Apeiron in exchange for approximately 10.97 million newly issued Class A shares, implying equity value of approximately €100 million ($115 million)

  • Company completed 1-for-10 reverse stock split effective October 29, 2026, with trading on split-adjusted basis beginning that date

  • Two sponsorship agreements accounted for substantially all sponsorship revenue for the nine months ended September 30, 2026; one settled in advertising/marketing services and one in equity securities of counterparty

  • Management concluded substantial doubt exists about company's ability to continue as going concern within twelve months due to recurring losses and need for additional capital

  • Company ended Q3 2026 with $12.1 million cash and cash equivalents, down from $19.6 million at June 30, 2026, and marketable securities of $8.1 million representing equity investment in Rezolve

  • Enhanced OS beta launched November 12, 2026, and HHS Peptide Policy enabled expanded peptide offerings effective November 3, 2026

Key metrics

Total revenue - Q3 2026Q3 2026
$3.3 million
Total revenue - Q2 2026Q2 2026
$17.7 million
Total revenue - 9 months 2026Nine months 2026
$21.0 million
Sponsorship revenue - Q3 2026Q3 2026
$2.6 million
DTC revenue - Q3 2026Q3 2026
$0.7 million
Net loss - Q3 2026Q3 2026
$13.5 million
Net loss - Q2 2026Q2 2026
$61.9 million
Net loss - 9 months 2026Nine months 2026
$91.8 million

Disclosure changes

  • Subsequent events - reverse stock split

    Company effected 1-for-10 reverse stock split effective October 29, 2026; every ten shares of Class A and Class B common stock combined into one share; fractional shares rounded up; par value and authorized shares unchanged

    Reverse split reduces share count significantly and affects per-share metrics; all historical share and per-share data retroactively restated
  • Subsequent events - DEAG acquisition

    Company announced proposed acquisition of approximately 77% of DEAG Deutsche Entertainment AG from Apeiron and other shareholders in exchange for approximately 10.97 million newly issued Class A shares; implied equity value of approximately €100 million ($115 million) for 100% of DEAG; concurrent $15 million private placement announced

    Transformational acquisition would add scale in live entertainment and ticketing; related party transaction negotiated by special committee
  • Subsequent events - HHS peptide policy

    HHS issued interim policy (October 28, 2026) not taking enforcement action against compounding six peptides; company began offering six additional peptides through Live Enhanced platform effective November 3, 2026

    Regulatory development enables expanded peptide product offerings on Live Enhanced platform
  • Subsequent events - Enhanced OS launch

    Company announced and launched beta version of Enhanced OS on November 12, 2026; AI-powered platform designed to provide personalized health, performance, and wellness solutions

    New AI-powered platform represents significant product development for Live Enhanced business
  • Subsequent events - lock-up extension

    Apeiron and CEO Maximilian Martin agreed to extend lock-up restrictions on 3.1 million shares through May 8, 2027; approximately 2.1 million shares released on November 8, 2026 instead of 5.2 million

    Extension of lock-up restrictions affects float and potential selling pressure
  • Marketable securities

    Company holds $8.1 million in marketable securities representing equity investment in Rezolve Ai PLC; received 3,731,343 Rezolve ordinary shares at $2.34 per share in September 2026; additional shares expected on December 23, 2026 to fulfill $10 million total consideration

    Company holds equity position in sponsor; fair value changes affect financial results

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow ENHA in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert